Insider Selling Xenon Pharmaceuticals Inc. Director Sells 601,640.00 in Stock
| XENE Stock | USD 38.52 1.10 2.78% |
About 61% of Xenon Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Xenon Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Xenon Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Xenon Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Xenon |
Xenon Pharmaceuticals Inc. Director Steven Gannon sold 13,000 shares of the businesss stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of 46.28, for a total value of 601,640.00. Following the completion of the sale, the director now owns 2,000 shares
Read at thelincolnianonline.com
 |
Xenon Pharmaceuticals Fundamental Analysis
We analyze Xenon Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xenon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xenon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Xenon Pharmaceuticals is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Xenon Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Xenon Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Xenon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Xenon Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Xenon Pharmaceuticals Related Equities
| REPL | Replimune | 16.86 | ||||
| VTYX | Ventyx Biosciences | 6.88 | ||||
| ANAB | AnaptysBio | 6.50 | ||||
| VRDN | Viridian Therapeutics | 6.27 | ||||
| MGTX | MeiraGTx Holdings | 5.56 | ||||
| IDYA | Ideaya Biosciences | 4.37 | ||||
| CRNX | Crinetics Pharmaceuticals | 3.78 | ||||
| PCVX | Vaxcyte | 3.36 | ||||
| KROS | Keros Therapeutics | 3.23 | ||||
| UTHR | United Therapeutics | 2.52 | ||||
| ASND | Ascendis Pharma | 2.29 | ||||
| MRUS | Merus BV | 0.74 | ||||
| CYTK | Cytokinetics | 0.17 | ||||
| ACLX | Arcellx | 0.14 | ||||
| NUVL | Nuvalent | 0.20 | ||||
| INBX | Inhibrx | 0.37 | ||||
| LYEL | Lyell Immunopharma | 1.72 | ||||
| EWTX | Edgewise Therapeutics | 1.72 | ||||
| KRON | Kronos Bio | 1.98 | ||||
| DYN | Dyne Therapeutics | 4.33 |
Complementary Tools for Xenon Stock analysis
When running Xenon Pharmaceuticals' price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |